Newsletter December 2025
Season’s Greetings & Thank You
As we approach the end of the year, we want to take a moment to thank you sincerely for your trust in partnering with us to accelerate your preclinical oncology drug development programs. This year has been marked by meaningful progress in preclinical oncology research, and we are proud to have supported advances across a wide range of tumor types, therapeutic modalities, and both in vivo and in vitro disease models.
2025 Highlights
This year brought several important scientific contributions from our team, underscoring our commitment to advancing preclinical oncology research. Highlights include:
Scientific Publications
- 13 Peer-reviewed, high impact publications EPO has co-authored
- Most prominent the paper main-authored by our colleague Simone Rhein published in “Blood” on how a CD22-specific T-Cell Receptor enables effective adoptive T-Cell therapy for B-cell malignancies
Events & Scientific Presentations
Throughout 2025, we were proud to share our scientific expertise at a select number of national and international conferences as well as at numerous industry gatherings. In addition to our own presentations, we attended numerous scientific and partnering events throughout the year to stay closely connected with the oncology community in science and business.
This year’s key highlights:
- AACR Annual Meeting: EPO presented 2 scientific talks and 3 posters, showcasing our latest findings in tumor biology, therapeutic response, and advanced in vivo and in vitro models.
- EPO Spring Symposium: Our annual scientific symposium in Berlin brought together partners and collaborators for in-depth discussions on emerging approaches in preclinical oncology and the translation of novel modalities and also on future collaborations.
Expansion of Our Service Offering
In 2025, we continued to expand and refine our preclinical oncology platform to better support your service programs. New models, enhanced technologies, and extended capabilities now enable even more precise, data-driven decision-making throughout drug development.
New and expanded capabilities include:
- Additional well characterized PDX, including pediatric and new orthotopic models
- Extended in vitro platforms, including live cell imaging and lab-on-chip blood brain barrier models
- Strengthened capabilities for immuno-oncology, Bites, ADCs, and targeted cell therapies
- Extended capabilities for targeted radionuclide therapy
- Blaze Ultramicroscopy and other mechanism-validation technologies
If you’d like to revisit the key topics we covered this year, you can find them all collected in our 2025 newsletter compilation.
Looking ahead, we will continue building on this momentum.
Thank you once again for your trust, collaboration, and continued partnership throughout the year 2025!
We look forward to driving more advancements together in the coming year and wish you a restful holiday season and a successful start to the New Year 2026.
Best Regards,
Jens Hoffmann (CEO), Antje Wengner (CSO), Wolfgang Walther (CSO)
EPO Berlin-Buch